Drug Approval | March 09, 2023
Eugia Pharma receives USFDA approval for Lenalidomide Capsules
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
The drug will be available in 600 hospitals and 105 DTPs
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
The investment will accelerate the overall Sarclisa development program
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
Subscribe To Our Newsletter & Stay Updated
